← Leaderboards
Kristopher R Bosse
Children'S Hosp Of Philadelphia
$2,270,831
Attributed
$2,270,831
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $634.5K · FY2018–25$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,270,831 · 2
By mechanism
R37$1,259,856 · 1
K08$1,010,975 · 1
Top collaborators
No co-investigators on record.
Most similar at Children'S Hosp Of Philadelphia
Same institution · by research overlap
- Crystal Mackall$19,988,621
- Robert Walter Schnepp$841,320
- Timothy Steven Olson$1,425,794
- Yael P Mosse$12,182,604
- John M Maris$30,818,378
Others in their field
Other Emerging Leaders on “Mouse Model”
- James Dale Berry · Brigham And Women'S Hospital$25,017,559
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$13,186,126
- Nuno Macarico Da Costa · Allen Institute$11,726,937
- Forrest Christie Collman · Allen Institute$11,726,937
- Jacqueline K White · Jackson Laboratory$11,670,339
- Thomas Dick · Rbhs-New Jersey Medical School$11,611,284
Research focus
Mouse ModelMalignant NeoplasmsMediatingImmunotherapeutic AgentLaboratoriesMalignant Childhood NeoplasmDesignImmunotherapyEngineeringImmuneIn VitroIn VivoChildLinkCell SurfaceCombatComorbidityCytotoxicityAntibodiesDifferential ExpressionGlypicanHigh RiskCancer ImmunotherapyNeuroblastoma
Grant awards (7)
GPC2 CARs in neuroblastoma: Mechanisms of resistance and efficacy of next-generation constructs$625,372
R37 · FY2025 · CA · contact PI
GPC2 CARs in neuroblastoma: Mechanisms of resistance and efficacy of next-generation constructs$634,484
R37 · FY2024 · CA · contact PI
Targeting the GPC2 oncoprotein with immune-based therapies in neuroblastoma$202,195
K08 · FY2022 · CA · contact PI
Targeting the GPC2 oncoprotein with immune-based therapies in neuroblastoma$202,195
K08 · FY2021 · CA · contact PI
Targeting the GPC2 oncoprotein with immune-based therapies in neuroblastoma$202,195
K08 · FY2020 · CA · contact PI
Targeting the GPC2 oncoprotein with immune-based therapies in neuroblastoma$202,195
K08 · FY2019 · CA · contact PI
Targeting the GPC2 oncoprotein with immune-based therapies in neuroblastoma$202,195
K08 · FY2018 · CA · contact PI